IMPORTANCE More effective, tolerable interventions for bipolar depression treatment are needed. Transcranial direct current stimulation (tDCS) is a novel therapeutic modality with few severe adverse events that showed promising results for unipolar depression.
B ipolar disorder presents a high burden.
1 Depressive episodes are more frequent, prolonged, and incapacitating compared with manic ones.
2 Therapeutic options for bipolar depression (BD) have adverse effects and modest efficacy.
3 Electroconvulsive therapy, although effective for BD, 4 requires sedation, short-term hospitalization, and pharmacologic adjustments. Repetitive transcranial magnetic stimulation, a noninvasive brain stimulation approach, showed positive results for unipolar depression 5 and BD. 6, 7 However, repetitive transcranial magnetic stimulation is expensive and associated with seizures. 8 Transcranial direct current stimulation (tDCS) is another noninvasive brain stimulation modality that applies weak, direct currents into the brain via electrodes that are placed over the scalp. Repetitive transcranial magnetic stimulation and tDCS are usually applied over the dorsolateral prefrontal cortex (DLPFC), a brain area whose metabolism increases after successful antidepressant treatment. 9 Moreover, the DLPFC, part of the frontoparietal network that is responsible for cognitive control and emotion regulation, is hypoactive in depression. 10 Antidepressant effects of noninvasive brain stimulation might involve, according to the factors of stimulation, modulation of the DLPFC and other brain structures implicated in the depression pathophysiology via enhancement of synaptic plasticity and metabolic activity, as well as excitability changes.
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Meta-analyses 14, 15 and randomized sham-controlled trials [16] [17] [18] showed tDCS efficacy for unipolar depression. Moreover, tDCS has clinical advantages, such as low cost, portability, and ease of use.
However, to our knowledge, no randomized shamcontrolled trial using tDCS has been conducted for BD. Therefore, we examined the efficacy and safety of tDCS as an add-on therapy in patients with BD who were receiving concurrent pharmacologic therapies in the Bipolar Depression Electrical Treatment Trial (BETTER). We hypothesized that active vs sham tDCS would have greater antidepressive effects, as measured by changes in the 17-item Hamilton Depression Rating Scale (HDRS-17) scores, after 6 weeks of treatment. The secondary outcomes were to compare the effects of treatment on other depression scales, cumulative response and remission rates, and rate of adverse events (AEs), particularly episodes of treatment-emergent affective switch (TEAS), between groups. We hypothesized that active compared with sham tDCS would also effect greater depression improvement in the other efficacy outcomes and that both groups would present similar AE rates.
Methods
BETTER was conducted at University Hospital, University of São Paulo, São Paulo, Brazil, from July 1, 2014 , to March 30, 2016 . BETTER used a parallel design in which 59 patients were randomly assigned to sham or active tDCS per a computergenerated list, using random block sizes. We used opaque, sealed envelopes with a corresponding code for group allocation. The study protocol was previously published 19 and executed with no significant changes; the protocol is also available in Supplement 1. The study was approved by the local (Comitê de Ética em Pesquisa do Hospital Universitário da USP and Comitê de Ética em Pesquisa do Hospital das Clínicas da Faculdade de Medicina da USP) and national (Comissão Nacional de Ética em Pesquisa) ethics committees and reported according to CONSORT guidelines. 20 All participants signed informed consent forms that met the Declaration of Helsinki guidelines 21 ; there was no financial compensation.
Participants
Participants were recruited through media advertisements and physician referrals. They were prescreened by brief telephone and email interviews, and those who met the general criteria were subjected to additional on-site screening. All participants were screened on site by trained, board-certified psychiatrists (5 of us: B.S.-J., L.B., E.C., L.V.A., and I.K.) who used the Mini-International Neuropsychiatric Interview 22 to perform the diagnosis of bipolar disorder (type I or II or not otherwise specified) in a major depressive episode and other comorbid mental disorders, such as anxiety disorders and the disorders listed as exclusion criteria in the study. Only those with HDRS-17 scores higher than 17 and low suicide risk (evaluated clinically and using the corresponding Mini-International Neuropsychiatric Interview questionnaire) and aged between 18 and 65 years were included.
We included only patients who presented lack of clinical response after 1 or more adequate pharmacologic interventions in the acute depressive episode. Thus, those who were receiving previous pharmacotherapy for the maintenance phase of bipolar disorder and presented an untreated depressive episode were not included.
For adequate pharmacologic intervention, we considered first-, second-, or third-line pharmacotherapies per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for bipolar I and II depressive episodes 23 : lithium, lamotrigine, quetiapine, olanzapine, valproate sodium, and electroconvulsive therapy were considered to be valid overall for bipolar I and II depressive episodes, whereas antidepressant monotherapy (for patients without episodes of hypomania/ mania in the past 5 years and no history of affective switches or mixed depressive episodes) and carbamazepine were considered to be valid third-line therapeutic interventions for bipolar II and I depressive episodes, respectively. The use of benzodiazepines was allowed but tapered to a maximum of diazepam, 20 mg/d, or its equivalent. We included only patients who had been receiving a fixed pharmacologic regimen for 4 weeks, which remained stable during the trial. All drugs were being used in their recommended dose range for BD, including blood levels within the therapeutic range for maintenance when applicable.
Exclusion criteria were demonstrating a depressive episode with mixed features; other psychiatric disorders, such as unipolar major depressive disorder, schizophrenia, substance dependence and abuse, and dementias; personality disorders; neurologic disorders; pregnancy; specific contraindications to tDCS (eg, metal plates in head); and participation in previous tDCS trials. The only psychiatric comorbidities allowed were anxiety disorders.
Patient losses occurred if they (1) missed 3 nonconsecutive sessions or 2 consecutive sessions during the initial 10-day stimulation period; (2) did not return at weeks 4 and 6; (3) presented serious clinical or psychiatric events during the trial, such as seizures, suicidal attempt/ideation, or fullblown manic or hypomanic episode; (4) were excluded for safety reasons, including severe worsening of psychiatric condition or serious AEs; or (5) withdrew participation at their request.
In cases of possible exclusion due to safety reasons or serious clinical or psychiatric events, participants would be evaluated separately by a psychiatrist from the hospital who was not participating in the study. Such cases, however, did not occur during the trial.
Intervention
Patients lay in comfortable, reclinable chairs to receive tDCS (devices, sponges, and headgears [EASYstrap] ; SoterixMedical), performed by blinded, trained nurses. Patients received no specific instructions during the sessions; they could read or use their smartphones, but not fall asleep. Communication with staff was minimal. The anode and cathode electrodes were inserted in 5 × 5-cm saline-soaked sponges and placed over the left and right DLPFC, respectively. The EASYstrap was used for positioning the electrodes over the DLPFC bilaterally per the omnilateral electrode system, which is optimized for peak electric current densities over the DLPFC, compared with other methods, such as the electroencephalographic International 10-20 System.
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Twelve 2-mA sessions (current density, 0.80 A/m 2 , ramp-up and ramp-down periods of 30 and 15 seconds, respectively) were applied for 30 minutes each day over 10 consecutive sessions once daily from Monday through Friday, with weekends off, and 2 sessions were applied at weeks 4 and 6 (study end point). Patients were granted 2 missing visits during the initial phase, which were replaced at the end to complete 10 sessions, as described elsewhere.
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The same treatment schedule was used in previous studies, 17, 26 making the results comparable. The end point at week 6 was chosen because tDCS effects tend to increase over time and are usually not significant after the acute treatment phase. The extra sessions at weeks 4 and 6 were planned for enhancing clinical effects and adherence.
The tDCS devices had a keypad on which a 6-digit code was entered to deliver active or sham stimulation. Sham tDCS was delivered using the same protocol and current intensity, but the period of active stimulation was only 30 seconds. Blinding was assessed at the study end point by asking participants to guess to which group they were assigned.
Outcomes
All assessments were performed by trained, blinded psychiatrists and psychologists. Participants were assessed at baseline, week 2, week 4, and the end point (week 6). Adverse events were recorded at weeks 2 and 6.
The primary outcome was the change in HDRS-17 score between groups over time. Secondary outcomes included (1) changes in the Montgomery-Åsberg Depression Rating Scale and Clinical Global Impression (CGI) depression scale scores; (2) rates of AEs, evaluated per a commonly used tDCS AE questionnaire 27 and the Young Mania Rating Scale; (3) sustained clinical response (defined as a sustained >50% reduction from baseline HDRS-17 score from all weeks greater than 2, or 4, or 6, since the time that a >50% reduction was first achieved) and remission (sustained HDRS-17 score ≤7 from all weeks greater than 2, or 4, or 6, since the time an HDRS-17 score ≤7 was first achieved). Therefore, patients who presented more than a 50% reduction from baseline scores or HDRS-17 ≤ 7 at weeks 2 and/or 4, but not at week 6, were not classified as presenting a sustained clinical response or remission, respectively.
Statistical Analysis
The sample size was estimated for a power of 80% and a 2-tailed α level of 5%. The effect size and variability of the difference between active tDCS and sham were based on the results of the meta-analysis available when this study was conceived (Hedges g, 0.74; 95% CI, 0.21-1.27) 17 and in a unipolar tDCS trial 14 (difference of 5.6 points; 95% CI, 1.3-10), which means that any effect size lower than these values would not be considered clinically significant. We obtained total sample sizes of 55 and 52 participants, respectively. After that, we considered an attrition rate of 10% to 15%, increasing the targeted sample size to 58 to 60 participants. Data were analyzed in the intention-to-treat (ITT) sample.
For continuous outcomes, we performed hierarchical linear model analyses, assuming a linear relationship over time with 4 repeated measurements per person, because patients were tested in regular intervals of 2 weeks. Measurements closer in time were considered to be more highly correlated than measurements further apart; thus, an autoregressive covariance structure was assumed. Time and tDCS as well as their interaction served as independent variables in the model. This model uses all available observed variables without the need to utilize other imputation methods for intention-to-treat analysis.
Our hypothesis was that the interaction of time with tDCS would be significant, with active tDCS showing significantly superior symptomatic decrease over time. Parameters were computed using maximum likelihood estimation to permit comparisons of nested models with χ 2 likelihood ratio tests. Models were computed with Satterthwaite approximation to degrees of freedom.
Sustained response and remission curves of the interventions were compared using failure (to account for events increasing over time) Kaplan-Meier survival curves. Data on patients lost to follow-up were examined only during the known period of observation. According to our definition of sustained response/remission, the event could only occur once. The Cox proportional hazards model was used to estimate the hazard ratios associated with the intervention.
The frequency of symptoms that were suggestive of TEAS, defined as Young Mania Rating Scale scores higher than 8, 28 and AEs were compared between groups by Fisher exact test or χ 2 test. Effect size was calculated as number needed to treat (NNT) for all outcomes. For continuous outcomes, effect sizes as well as their 95% CIs were estimated based on the model residual SD 29 and then transformed to NNT using the cumulative distribution function of the standard normal distribution. 30,31 For survival analyses, NNT was estimated based on a previous study.
32 Number needed to treat assesses the effectiveness of clinical interventions, wherein a higher NNT reflects a less effective intervention. Analyses were performed using Stata, version 14.2 (StataCorp) and R, version 3.4.0 (lme4 package; R Foundation). Results were significant at P < .05.
Results

Participants
Of 912 volunteers, 221 individuals were screened and 162 were excluded for several reasons. Of the 59 patients included, 52 (26 in each group) received all 12 tDCS sessions and completed the final assessment ( Figure 1 ; Table 1 ). (33) 18 (31) Severe depression 14 (48) 14 (47) 28 (47) Generalized anxiety disorder 22 (76) 24 (80) 46 (78) Panic disorder 3 (10) 1 (3) 4 (7) Social anxiety disorder 6 (21) 6 (20) 12 (20) Any anxiety disorder 25 (86) 26 (87) 51 ( Figure 3A) . Similarly, 10 and 5 patients in the active and sham groups, respectively, presented sustained remission. The cumulative survival rates were 37.4% (95% CI, 22%-58.5%) and 19.1% (95% CI, 8.4%-40%). The Cox proportional hazards ratio was 2.07 (SE, 1.13; 95% CI, 0.71-6.06; P = .18). The NTT was 5.46 (95% CI, 3.38-14.2) ( Figure 3B ).
Other Depression Measures
As in the primary outcome, a significant time × group interaction was found in Montgomery-Åsberg Depression Rating Scale (F 1,167.6 = 5.23; P = .02). Patients in the active group experienced significantly greater improvement over time compared with those in the sham group (β int = −1.99; NNT, 6.4; 95% CI, 3.5 to 47.1). Equivalently, including the slope as a random factor did not significantly improve the model fit (χ 2 2 =5. 64; P = .06). For the CGI scale, no significant differences could be found in the trajectories of symptomatic decrease (F 1,162.31 = 2.31; P = .13) (eTable in Supplement 2).
AEs and Safety
Skin redness rates were higher in the active (54%) than sham (19%) group (P = .01) at the end point. The frequency of other AEs did not significantly differ ( Table 2 ). There were 9 TEAS episodes throughout the trial: 5 (19%) in the sham and 4 (15%) in the active group (χ 2 = 0.13; P = .71). These episodes did not meet the criteria for a major depressive episode with mixed features, hypomania, or mania per DSM-5 guidelines and required no hospitalization, trial discontinuation, or specific treatment ( Table 2) .
Integrity of Blinding
In the sham and active groups, respectively, 15 and 16 (of 26 participants for both) patients correctly identified the allocation group (χ 2 = 1.92, P = .16). Thus, participants were unable to guess their actual group beyond chance.
Discussion
In accordance with our primary hypothesis, active tDCS showed superior symptomatic improvement, based on HDRS-17 scores, 
Active tDCS
Survival analyses for sustained response (defined as a sustained >50% reduction from baseline 17-item Hamilton Depression Rating Scale score from all weeks greater than 2, 4, or 6, since the time that a >50% reduction was first achieved) (A) and sustained remission (sustained HDRS-17 score Յ7 from all weeks greater than 2, 4, or 6, since the time that an HDRS-17 score Յ7 was first achieved) (B). Those who received tDCS significantly more frequently developed skin redness. The results also suggest that the frequency of itching and burning was higher in the active group. These AEs are often reported after active tDCS 18, 34, 35 and seem to be caused by the injected current in the skin. Nonetheless, there were no losses due to these AEs, which were shortlived. Also, these AEs did not affect blinding.
Transcranial DCS was tolerable and safe, with both groups presenting similar TEAS rates, which is a concern when treating depression with tDCS.
36 Such a feature is advantageous compared with other pharmacologic interventions presenting higher rates of TEAS and other AEs. 23, 37 No patient receiving antidepressant monotherapy presented affective switches during the trial.
Active tDCS was superior to sham for sustained response, but not for sustained remission. These outcomes measure different clinical concepts. Response aims to measure whether the intervention provides significant (although not necessarily complete) clinical relief of depressive symptoms, whereas, remission would reflect a category in which symptoms are minimal or absent. 38 Both definitions are based on arbitrary thresholds and have received some criticism.
39 Notwithstanding, only approximately half of responders are also remitters. 38 Thus, our remission analyses might have been underpowered. Another possibility is that our tDCS protocol could not achieve remission. As tDCS effects per se are subtle, inducing small changes in the membrane potential, greater effects may be achieved when simultaneously combining tDCS with other treatments (eg, pharmacotherapy, other brain stimulation therapy, or psychotherapy).
13 Therefore, different tDCS protocols, particularly combination therapies, could be explored in further studies.
BETTER was devised as an add-on tDCS trial in patients with BD, representative of a real-word setting, with a high prevalence of comorbid anxiety disorders. 40, 41 Moreover, onethird of the enrolled patients presented a depressive episode after at least 2 adequate treatment regimens, 1 of them being a first-line treatment per CANMAT guidelines. 23 Although there is no consensus on the definition of treatment-resistant BD, it is proposed that the concept should capture the "resistance" to the next treatment step, 33 which is in line with the operationalization that we adopted. Furthermore, most patients were receiving antidepressant drugs as an adjuvant treatment to mood stabilizers. Although not recommended by guidelines, 42 antidepressants are widely used for BD. 43 Other studies evaluating tDCS efficacy in BD are limited by their open-label design and/or mixed unipolar-bipolar sample. 16, [44] [45] [46] A meta-analysis evaluating tDCS efficacy in BD showed that tDCS effected a moderate to large depression improvement, 47 as observed in our study. Moreover, our clinical efficacy was similar to that observed in repetitive transcranial magnetic stimulation and tDCS unipolar depression trials.
5,17
Limitations
The first limitation of the trial is that active tDCS was not superior to sham for CGI scale scores. This scale might not have been sensitive for our sample, composed of outpatients who were not severely ill. In addition, the CGI scale lacks precision and anchor points, making generalization between physicians and researchers difficult. 38 We could not use an "improved" CGI scale, which presents additional information and is helpful to grade patients in the moderate severity range, 48 as it has not been validated in Portuguese. Second, even using proper randomization techniques, there were imbalances in the random distribution of some baseline variables owing to small sample size. a Adverse events were assessed using a commonly used tDCS questionnaire.
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At the end of weeks 2 and 6, all participants were asked to complete these questionnaires, describing the presence of an adverse event, its severity (mild, moderate, or severe), and its relationship to the treatment (1, none; 2, remote; 3, possible; 4, probable; or 5, certain).
b P values were determined with χ 2 or Fisher exact test.
Conclusions
Transcranial direct current stimulation was an effective and tolerable add-on treatment in this subsample of patients with type I or II bipolar disorder who were in a major depressive episode, with similar rates of treatment-emergent affective switches compared with sham. Although preliminary, our results are promising and encourage further trials to examine the efficacy of tDCS in a large bipolar disorder sample. intensity and continuous electric current in the cerebral cortex via electrodes placed on the scalp in order to modify the cerebral activity in the area where the current is applied. In a previous study of the group, it was observed that tDCS is as effective as the antidepressant sertraline in the treatment of unipolar depression. Moreover, it was observed that the tDCS has low side effects. Because of the encouraging results previously found, we decided to investigate whether tDCS is an effective treatment for Bipolar Depression. The study will be a double-blind clinical trial in which 60 patients with Bipolar Depression will be randomly assigned to two groups, one of them tDCS will be performed and the other to receive sham tDCS. At the end, it will be evaluated which group -active or sham tDCS -will display decrease of depressive symptoms.
Whether it is noticed that active tDCS has a better outcome than sham tDCS, the present study will provide evidence of a possible new, non-pharmacological treatment for Bipolar Depression, which would have an important impact on quality of life of that patients.
Key words: Transcranial Direct Current Stimulation; Bipolar Depression; Non-invasive Brain Stimulation; Bipolar Disorder.
Problem Statement
Bipolar Disorder (BD) is a psychiatric disorder characterized by the presence of episodes with clinically significant symptoms of hypomania or mania frequently alternated by periods of normal mood and depression. The estimated lifetime prevalence in Brazil is approximately 0.9 to 2.1% (Merikangas et al., 2011) . BD generally starts (up to 60% of cases)
in late adolescence or early adulthood. It is recurrent, with mood swings frequently present throughout the life, with depressions being more prevalent than euphoria, occurring in up to 1/3 of the lifetimes of the patients. Morbidity and mortality rates are high, including suicide risk, that reach up to 15% (Geddes & Miklowitz, 2013; Yatham et al, 2013) . In addition, changes in the neurotransmission systems of gabaergic, glutamatergic and neuropeptides were also found (Geddes & Miklowitz, 2013; Phillips & Kupfer, 2013) .
Patients with BD present difficulties in several cognitive domains, even euthymic, being the executive functions (which regulate and monitor cognitive processes and involve planning, operational memory, attention, problem solving, inhibitory control and mental flexibility) one of the most impaired. Executive dysfunctions may, in part, explain difficulties in the psychosocial adaptation of patients with BD. During mood changes, even subtle, impairments of attention, memory, psychomotor speed and learning are commons (Depp et al, 2012) . Therefore, BD etiopathogenesis seems to include, in addition to modifications in neurotransmitters, complex structural and functional changes in neuronal plasticity and in brain circuits influenced by genetic and environmental factors.
DSM-V continues to divide bipolar disorders into: type I, characterized by the presence of a manic episode, emphasizing the need of the presence of increased activity or energy; type II, characterized by the alternation of hypomanic and depressive episodes (this is not, however, understood as a more attenuated form of the disease, since individuals spend a lot of time in depression and have relevant consequences due to the constant mood instability); cyclothymic disorder in which symptoms of mood elevation alternate with depressive symptoms for at least 2 years (and for children a minimum of 1 year) without, however, meeting criteria for manic, hypomanic or depression episodes. Differently to DSM-IV-TR, previous version, mixed episodes (explained in more detail below) are no longer an independent category but may be present during episodes of mania / hypomania or major depression. Other specifiers added were "with anxiety" (at least 2 of the following symptoms: tension, restlessness, trouble concentrating from worry, fear that something horrible might happen, feeling of loss of control of self) and "suicidal risk."
Suicide is the leading cause of early mortality in that patients, who have a 28-fold increased risk of suicidal behavior compared to the general population. The ratio of suicide attempt to full-blown suicide in BD is 5: 1 versus 15: 1 in the general population, indicating that these patients tend to use more violent and lethal methods. The relationships between suicidal behavior and BD seem to be more striking than in other psychiatric disorders, being the most important among men and secondarily among women. From 20% to 55% of BD patients have already had at least one lifetime suicide attempt and complete suicide rates are between 10%
and 15% (Goodath and Jamison, 2007; Yatham et al, 2013) .
The goal of TB treatment is to achieve euthymia, promote the prevention of new episodes, and the recovery of social and occupational functioning. Once the treatment is carried out throughout the life, attention must be paid to its long-term effects and its possible health damage. BD is still a difficult-to-treat psychiatric condition, especially bipolar depression, mixed states, and rapid-cycling. Therapeutic options for depression can worsen the phases with manic symptoms and medications for mania can bring a later depression. The limited knowledge of the etiology of BD hampers the development of specific treatments (Geddes & Miklowitz, 2013) .
The ideal mood stabilizer would has antidepressant and antimanic efficacy, without inducing symptoms of opposite polarity to that in treatment and having efficacy in prevention of new episodes, both depressive and manic. The simpler and with fewer side effects the better the adherence to treatment. Despite this, it is common to combine the use of two or more mood stabilizers in the treatment of an acute episode or even in prophylactic treatment. BD is a disease that affects the individual throughout life, with periods of euphoria and more frequently depression and is associated with an important family risk. Clinical and psychiatric comorbidities are frequent. The treatment is complex and varies according to the patients' symptoms. In spite of the numerous efforts made so far, new therapeutic perspectives are still needed to improve the quality of life of this population and of all linked to them.
In this context, Transcranial Direct Current Stimulation (tDCS) is a new therapeutic intervention that has been presenting a fast development in recent years, seeming to be a promising technique in the therapy of many neuropsychiatric disorders (Fregni & PascualLeone, 2007) . The technique consists of applying a low intensity of continuous electric current to the brain via electrodes placed on the scalp. It has been demonstrated that, using adequate doses, electrodes and equipment, a significant amount of electrical current reaches the neural networks (Miranda, Lomarev & Hallett, 2006) , leading to neuromodulation (Nitsche et al 2003) .
Most standard protocol of the technique uses two surface electrodes -one as a cathode and the other anode . The anode is usually applied over the area of the brain to be stimulated and the cathode is applied either in the opposite hemisphere or in a saline solution.
An electric current of one or two milliampares lasting 20 minutes is applied . It is believed that the anode exerts an excitatory effect on the applied region, by depolarizing the neurons, whereas the cathode exerts an inhibitory effect by hyperpolarizing the neurons of this region (Been et al, 2007) . Some translational studies have already demonstrated the clinical utility of this method, for example, in decreasing smoking craving (Fregni et al, 2008) , improving the cognitive performance of elderly people with Alzheimer's disease (Ferrucci et al, 2008) and reducing pain in patients with fibromyalgia (Roizenblatt et al, 2007) .
Our group conducted a double-blind, factorial, randomized, placebo-controlled, doubleblind clinical trial with 120 patients allocated to 4 groups: sham tDCS/placebo; sham tDCS/sertraline; active tDCS/ placebo; active tDCS/sertraline. Patients had moderate to severe depression and did not use antidepressants. The results, published in 2013 in the JAMA Psychiatry (Brunoni et al., 2013) , showed that the efficacy of the tDCS and sertraline were similar over the course of 6 weeks, that the active tDCS was superior to the sham tDCS, and that the tDCS combined with sertraline was superior to the other treatments. These findings open new doors for further research using tDCS as an alternative therapeutic for the treatment of depression. Current research seeks to define the therapeutic role of tDCS.
Rationale and Hypotheses
Clinically, bipolar depression is an important condition in which therapeutic alternatives have been poorly studied. In this line, we will be able to evaluate if the tDCS is a therapeutically effective alternative, and also with few side effects, for this population. This may bring shortterm clinical gains to the patients who do not tolerate antidepressants or have been refractory to them.
Expected Results
The main objective of the study is to compare the antidepressant effects of tDCS with sham tDCS in 60 refractory patients with bipolar depression who use mood stabilizers. The hypothesis is that active tDCS will have a greater antidepressant effect than sham tDCS in patients with bipolar depression. To test this, we will use the Montgomery-Åsberg Depression Scale (MADRS), the Hamilton Depression Scale 17 Items (HAMD-17), and the Beck Depression Inventory (BDI) to measure depressive symptoms early in the study (week 0), immediately after 10 tDCS sessions week 2), after the session of week 4 and immediately after the last session (week 6).
The secondary objectives to be explored are: (a) to assess the adverse effects associated with tDCS in bipolar depression, with emphasis to the hypomanic and manic switches. In a systematic review (Brunoni et al., 2011a) , no side effects linked to tDCS were found, however there are reports of hypomanic and manic switches episodes both individually and in combination with antidepressants. Thus, Young's mania rating scale will be applied at treatment weeks 0, 2, and 6; (b) to evaluate clinical predictors of antidepressant response, such as age, refractoriness, gender, type of bipolar disorder, drug class, chronicity, severity, and comorbidity with anxiety disorders.
Scientific challenges and methods
Design
We will conduct a controlled, randomized, double-blind clinical trial in which eligible patients will be recruited through specialized outpatient clinics, internal and external disclosure of the research project. They will be allocated to one of the groups: simulated stimulation group (sham tDCS) or active tDCS group (active tDCS). Patients who are randomized to the active tDCS group will place the anode and cathode on the right and left dorsolateral prefrontal cortex areas respectively (corresponding to F3 and F4 according to the EEG 10-20 system). Treatment will be applied consecutively for 10 days, excluding weekends and then once every two weeks until the end of the study at week 6. All subjects will be evaluated by the MADRS, YMRS, CGI HAMD-17 and BDI scales at weeks 0, 2, 4 and 6.
Volunteers who have undergone improvement and have been allocated to the active tDCS group may choose to voluntarily continue to receive active tDCS for 3 months with weekly sessions in order to maintain the benefits gained and provide maintenance data for the survey.
Randomization and allocation
Participants will be randomly distributed according to a computer-generated list. The assignment will be performed using sealed opaque envelopes containing the code corresponding to the group designated for each participant. This code will be imputed in the tDCS device that automatically provides active or sham stimulation, without the staff knowledge. For sham tDCS, the device stops the application of the current 30 seconds after its initiation, therefore, mimetizing the initial side effects on the skin (scratching, paresthesia), but without inducing neuromodulatory effects.
Inclusion and exclusion criteria
The study will include 60 adults (18-75 years), men or women, diagnosed with acute bipolar depression, despite an appropriate course of treatment with mood stabilizers. For inclusion, they should also have a score on the HDRS ≥ 17 scale, corresponding to a depressive episode of moderate to severe intensity. Finally, patients should be able to read and understand the portuguese language.
Exclusion criteria are: (1) other neuropsychiatric conditions, such as schizophrenia, drug dependence, dementia, cranial traumas, epilepsy, and so on (although participants with anxiety disorders may be included if the primary diagnosis is DB), (2) mixed states, defined as having simultaneously manic symptoms, measured by the Young Mania Scale (YRMS> 8); (3) pregnancy, (4) specific contraindications for tDCS, (5) serious clinical conditions. In relation to the use of psychoactive drugs, these should be in stable therapeutic doses for at least 6 weeks or without the use of psychotropic drugs. Benzodiazepine drugs will be allowed, although only at low doses (≤ 20mg / day of diazepam or equivalent).
Blinding
The study will be double-blind, that is, researchers, assessors and patients will not be aware of the treatment until the end of the study. The tDCS technique is particularly advantageous for ensuring blinding when compared to other non-invasive brain stimulation techniques. This is because the tDCS generates a slight tingling in the region of the application of the electrodes, in the first minutes of the intervention, generating no further effects. We will use an tDCS device that allows you to program a code in which the device automatically turns off the power without the need for an operator. This guarantees a double blindness.
Interventions
For true stimulation the anodes and cathodes will be placed respectively in the left and right dorsolateral prefrontal cortical areas (corresponding to F3 and F4 according to the EEG system 10-20). We will use 5 x 5cm electrodes, electric current of 2mA for 30 minutes daily.
This arrangement is known as bifrontal and has already been used in major depression studies (Kalu et al., 2012) . The tDCS will be applied for 10 consecutive days, excepting on the weekends and thereafter once every 2 weeks until the end of the study (week 6).
Clinical variables
Patients who will participate of the research will be evaluated by psychiatrists or clinical psychologists with appropriately trained for the purpose. The diagnosis will be confirmed using the Mini International Neuropsychiatric Interview (MINI). The MADRS, YMRS, CGI HAMD-17 and BDI will be applied at weeks 0, 2, 4 and 6.
Calculation of the sample size
Based on the meta-analysis of Kalu et al (2012) , which verified an efficacy favoring active tDCS vs. sham with a Hedges g of 0.743 (95% Confidence Interval = 0.21 to 1.27), for a two-tailed p of 0.05 and a power of 80%, the total sample size will be between 58 to 60 patients.
Statistical analysis
The primary analysis will be performed with analysis of variance of repeated measures (in 2 levels: active procedure and placebo) with the tDCS being the intra-groups independent variable and time (in 4 6 levels: week 0, 2, 4 and 6) the independent variable between-groups.
HDRS will be the dependent variable. Our hypothesis is that the interaction of tDCS over time will be significant, with active tDCS being superior to placebo at week 6. We will also use Global Clinical Impression and Depressive Symptomatology Inventory as dependent variables and we will make multivariate logistic regressions having response (reduction of HDRS ≥ 50%) and remission (HDRS ≤ 7) as dependent variables. Hypomanic and manic switches frequency (Young's Mania Scale> 8) will be compared between the groups using the Chi-square test or the 
Strategies to preserve adherence
The research and stimulation service will work throughout the afternoon, allowing the patient to choose the most appropriate time. In addition, the research assistant will make regular telephone and/or email contact with all participants to prevent absents. We will also allow three non-consecutive absences of patients during the fifteen days of stimulation, taking into account the problems of urban mobility in the city of São Paulo. Finally, we will run a one-week run-in between sorting and starting the search. Run-in lets you exclude participants who do not return to the beginning of the search, avoiding early dropouts. All the strategies described increase adherence to clinical trials (Fregni, Boggio & Brunoni, 2012) .
Ethical aspects and safety
tDCS is a technique used for approximately 12 years and no serious adverse events have been reported. Studies in animals show that the electrical dose required to cause brain injury is about two orders of magnitude (that is, 100 times) greater than that used in clinical practice (Liebetanz et al, 2009; Brunoni et al. 2011b) .; investigated the use of electric currents in high doses with the purpose of provoking tissue damage, observing that these occurred only from catodal stimulation above 100 A / m2, two orders of magnitude higher than those used in humans (always below 1 A / m2, with average densities between 0.4 and 0.8 A / m2). In a systematic review, we observed that the most serious side effects of the tDCS were tingling and mild discomfort at the application site (Brunoni et all 2011c) . Therefore, from the ethical point of view, tDCS seems to be a very safe technique with few adverse effects. In this clinical trial, patients taking antidepressants (since a stable dose 6 weeks ago) will be included. In addition,
we will evaluate patients 12 times over 6 weeks -in this way, we can quickly identify any worsening of the clinical picture and perform early intervention.
Data collection will only begin after approval of the project by the Research Ethics Committee and, for each volunteer, after signing the free and informed consent form. The study will also be prospectively registered on clinicaltrials.gov. All the procedures described present minimal risk. If a volunteer presents a risk of major suicide, he/she will be excluded from the study, adopting the standard procedure for the management of this type of patient (ie, if the outpatient management is possible, we will refer the patient to the family for treatment -if this we will be in contact with PS-Lapa, which is the reference for cases of this type). We will be in contact with Lapa Emergency Service of Psychiatry, which is the reference for cases of this type. Participants may have access to their data and may leave the study at any time, without impair to any treatment they may perform within the institution. The data will be collected, analyzed and published in order to preserve the anonymity of the individual. In addition, the study will be conducted in accordance with all requirements of the Research Ethics Committee and also based on the recommendations established in the Helsinki Declaration (1964), as amended in Tokyo (1975) , Venice (1983) and Hong Kong (1989).
As a benefit, participants will be able to participate in a clinical trial to treat their clinical condition. This will be possible even if they receive placebo stimulation, as they may receive active stimulation at the end of the study if they still persist with depressive symptoms. 
Timeline
Month
Dissemination and evaluation
The methods for evaluating the results obtained were previously described in the statistical analysis section of the data.
Among the products of the project, we highlight: (1) The results will be disseminated through presentation at congresses and scientific articles. Taking into account the originality of the study, the quality of previous publications of similar articles and the importance of the subject in medical practice, we believe that the clinical outcomes of this project will be published in a major impact journal, such as Biological 
